1.19
-0.05(-4.03%)
Currency In USD
| Previous Close | 1.24 |
| Open | 1.24 |
| Day High | 1.25 |
| Day Low | 1.19 |
| 52-Week High | 9.21 |
| 52-Week Low | 1.05 |
| Volume | 209,868 |
| Average Volume | 232,322 |
| Market Cap | 80.42M |
| PE | -0.67 |
| EPS | -1.78 |
| Moving Average 50 Days | 1.25 |
| Moving Average 200 Days | 2.53 |
| Change | -0.05 |
Climb Bio Appoints Edgar D. Charles, M.D., MSc as Chief Medical Officer
GlobeNewswire Inc.
Jun 18, 2025 11:00 AM GMT
Dr. Charles, Accomplished Immunology-Focused Drug Developer, Brings More Than 20 years of Biopharma Leadership, Clinical Development, and Operations Expertise Company Also Hires Cindy J. Driscoll, MBA, Financial Executive with Over Two Decades of Exp
Climb Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
May 19, 2025 8:34 PM GMT
WELLESLEY HILLS, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced that the Company has granted an indu
Climb Bio Appoints Seasoned Biotech Leaders to Board of Directors
GlobeNewswire Inc.
Apr 01, 2025 11:00 AM GMT
Appointments Include Industry Veterans Kim Cobleigh Drapkin, CPA, and Bo Cumbo as Independent DirectorsWELLESLEY HILLS, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM) today announced the appointments of biotech industry ve